Global Predictive Biomarkers Market Strategic Research Report

The global predictive biomarkers market sits at the intersection of precision oncology, companion diagnostics, and next-generation molecular profiling, representing one of the fastest-growing segments within the broader in vitro diagnostics landscape. Valued at approximately USD 8.4 billion in 2024, the market encompasses a diverse portfolio of genomic, proteomic, and epigenomic markers that guide treatment selection decisions across oncology, neurology, cardiovascular disease, and autoimmune conditions. The commercial significance of predictive biomarkers extends well beyond laboratory medicine — these molecular indicators directly influence drug approval pathways, clinical trial design, and payer reimbursement decisions, embedding them as essential infrastructure in the pharmaceutical development and personalised medicine ecosystem. As drug developers increasingly submit companion diagnostic co-submissions to regulatory agencies, the economic and strategic importance of predictive biomarkers continues to expand across both developed and emerging healthcare markets.

Three principal forces are accelerating market growth during the 2025–2032 forecast period. First, the accelerating adoption of targeted therapies and immuno-oncology agents — particularly PD-L1 inhibitors, KRAS-targeted compounds, and HER2-directed treatments — has created mandatory demand for validated predictive biomarker assays at the point of prescribing, institutionalising biomarker testing within standard-of-care protocols. Second, the widespread deployment of next-generation sequencing platforms and liquid biopsy technologies has dramatically reduced the cost per genomic test while simultaneously expanding the clinical information yield, enabling routine multi-gene panel testing in community oncology settings previously limited to academic centres. Third, regulatory agencies including the FDA and EMA have progressively tightened the co-development requirements linking drug approvals to companion diagnostic clearances, creating a sustained contractual pipeline for biomarker platform providers. A meaningful restraint, however, is the persistent lack of standardisation across biomarker assay platforms and reporting frameworks, which complicates cross-institutional data comparability and inhibits the adoption of novel markers in markets with fragmented laboratory infrastructure.

This report delivers a comprehensive, quantified assessment of the global predictive biomarkers market across the 2025–2032 forecast horizon, with historical context extending to 2019. It covers market segmentation by biomarker type, technology platform, and clinical application; regional and country-level revenue forecasts for all major geographies; detailed competitive profiles of ten leading companies; and forward-looking trend analysis. The report is designed to serve corporate strategy teams evaluating portfolio positioning, investment analysts conducting sector due diligence, M&A advisors assessing target valuations, and procurement managers navigating vendor selection decisions in clinical diagnostics.